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Abstract
Background: Allergen-induced imbalance of specific T regulatory (Treg) cells and T helper 2 cells plays a decisive role 
in the development of immune response against allergens.
Objective: To evaluate effects and potential mechanisms of DNA vaccine containing ovalbumin (OVA) and Fc fusion 
on allergic airway inflammation.
Methods: Bronchoalveolar lavage (BAL) levels of inflammatory mediators and leukocyte infiltration, expression of 
CD11c+CD80+ and CD11c+CD86+ co-stimulatory molecules in spleen dendritic cells (DCs), circulating CD4+ and CD8+ T 
cells, Foxp3+ in spleen CD4+ T cells and spleen CD4+ T cells were measured in OVA-sensitized and challenged animals 
pretreated with pcDNA, OVA-pcDNA, Fc-pcDNA, and OVA-Fc-pcDNA.
Results: OVA-Sensitized and challenged mice developed airway inflammation and Th2 responses, and decreased the 
proliferation of peripheral CD4+and CD8+ T cells and the number of spleen Foxp3+ Treg. Those changes with increased 
INF-γ production and reduced OVA-specific IgE production were protected by the pretreatment with OVA-Fc-pcDNA.
Conclusion: DNA vaccine encoding both Fc and OVA showed more effective than DNA vaccine encoding Fc or OVA 
alone, through the balance of DCs and Treg.
Introduction
Allergic asthma is a Th2 lymphocyte-associated inflam-
matory airway disease characterized by airway eosino-
philia, goblet-cell hyperplasia, variable airway
obstruction and hyper-responsiveness [1]. The balance
between allergen-specific T regulatory (Treg) cells and T
helper 2 cells appears to be decisive in the development of
the immune response against allergens [2]. Allergen-spe-
cific immunotherapy (SIT) has been suggested as one of
the few antigen-specific treatments for inflammatory dis-
eases, with a long-term of efficacy [2]. SIT could reduce
the development of asthma and bronchial responses in
patients exposed to inhaled allergens. It is possible to tar-
get anti-inflammatory therapy to the various pathways of
the disease, improving asthma control. However, the
mechanisms by which allergen-DNA-targeted dentritic
cells (DCs) plays anti-inflammatory roles remain unclear.
We found that allergen-DNA-targeted DCs reduced
Th2 responses and the expression of C co-stimulatory
molecules like D11c+CD80+ and CD11c+CD86+ in experi-
mental asthma [3]. The present study furthermore inves-
tigated the potential mechanisms where Treg cells and
spleen DCs may be involved in the therapeutic process of
DNA vaccination coding with Fc and ovalbumin (OVA-
Fc-DNA) in in allergic models. We determine the thera-
peutic role of immunization with OVA-Fc-DNA-targeted




Male BALB/c mice, 6-10 weeks old at the onset of experi-
ments, were purchased from Institute of Animal in Third
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Page 2 of 8Military Medical University (Chongqing, China). Animal
care and experimental procedures were in accordance
with the animal ethics regulations of the Home Office,
UK.
Construction of OVA-Fc-pcDNA3.1 immunization vector
To construct the DNA vaccine containing OVA and Fc
fusion gene targeting DCs, the murine OVAcDNA was
amplified from OVA-pcDNA3.1 plasmid by polymerase
chain reaction (PCR), spliced and then cloned into
pMIgV containing murine IgG2a Fc cDNA. OVA-Fc-
pcDNA3.1 plasmid was finally constructed after sub-
cloning spliced OVA-Fc into pcDNA3.1 plasmid. OVA-Fc-
pcDNA3.1 plasmids were then transfected into CHO
cells with lipofectamine. The expression of OVA and Fc
was determined by flow cytometry, Western blotting, and
enzyme-linked immunosorbent assay (ELISA). DNA
sequencing and restriction endonuclease digestion analy-
sis indicated that the eukaryotic expression vector OVA-
Fc-pcDNA3.1 had been constructed successfully. The
expression of OVA and Fc expression could be detected
in CHO cells by Western blotting, ELISA, and flow
cytometry, as shown in Fig. 1A and 1B. The PCR prod-
ucts of OVA and Fc were selected as target DNA frag-
ments and cloned into pcDNA3.1 (+) to construct the
recombinant plasmids OVA-pcDNA3.1 and OVA-Fc-
pcDNA3.1 respectively. The plasmids were propagated in
Escherichia coli and large scale purification of all plas-
mids was conducted with the EndoFree Plasmid Giga Kit
(Qiagen, Mississauga, Canada) according to the manufac-
turer's instructions.
Immunization protocols
BALB/c mice (8-wk-old, male, 20~25 g) were maintained
under standard conditions with free access to water and
rodent laboratory food. Mice were handled according to
experimental procedures involving mice [4]. Mice were
divided randomly into the following groups, A: PBS or
plasmid- vaccinated mice sensitized and challenged with
PBS, B: PBS- vaccinated mice sensitized and challenged
with OVA, C: pcDNA3.1 plasmid-vaccinated mice sensi-
tized and challenged with OVA, D: OVA- pcDNA3.1 plas-
mid-vaccinated mice sensitized and challenged with
OVA, and E: OVA-Fc-pcDNA3.1 plasmid-vaccinated mice
sensitized and challenged with OVA (n = 8 per group).
BALB/c mice were injected intramuscularly with 100 μg
of PBS, pcDNA, OVA-pcDNA and OVA-Fc-DNA in a
final volume of 100 μl 0.9% NaCl on day 0 and boosted
Figure 1 Construction of recombinant plasmid OVA-Fc-pcDNA3.1 (A) includes 1: DL 2 000 + DL 15 000 marker; 2: OVA-pMIgV/EcoR I + Xba 
I; 3:OVA-Fc-pcDNA/B gl II; 4: OVA-Fc-pcDNA/EcoR I; 5: PCR product of OVA-pcDNA3.1; 6: λDNA/EcoR I + Hind III; 7: OVA-pMIgV/EcoR I +Bgl 
II; 8: OVA-Fc-pcDNA/EcoR I+Xba I; 9: OVA-pMIgV/Bgl II+Xba I. The expression of OVA-Fc fusion protein was detected in OVA-Fc-pcDNA 3.1-trans-
fected CHO cells (B-1) and pcDNA3. 1-transfected CHO cells (B-2) by flow Cytometry. Immunization scheme of DNA vaccination prevention of avalbu-
lin (OVA)-induced allergic airway inflammation (C).
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The mice were then sensitized to OVA for the induction
of allergic asthma in BALB/c mice, as described previ-
ously [5]. OVA (grade V, 50 mg) adsorbed to 2 mg alumi-
num potassium sulfate (alum) was administered
intraperitoneally on days 24 and 38, followed by an inha-
lation of 1% OVA (grade II) diluted in PBS for 30 min on
days 38, 49, 50, and 51, respectively. Control mice
received the same processes with OVA and an inhalation
of PBS for 30 min and experimental design was shown in
Fig. 1C. Twenty four hours after the last challenge (day
52), mice were sacrificed, blood was taken, bronchoalveo-
lar lavage (BAL) was performed, lungs were removed and
fixed, and spleen DCs and CD4+T cells were isolated for
in vitro culture.
Determination of OVA- specific IgE levels in serum
Serum levels of OVA-specific IgE were determined by
ELISA. Briefly, 96 microtiter plates were coated overnight
with 100 μl of OVA (10 μg/ml in 0.1 mol carbonate buffer,
pH 9.6) at 4°C. The antigen-coated plates were washed
with PBST (0.5% Tween-20 in PBS) thrice. Mouse sera
were added and the plates were incubated with peroxi-
dase-conjugated anti-mouse IgE antibody (Southern Bio-
tech, USA) at 4°C overnight, and then washed with PBST
thrice before adding citric acid-phosphate buffer (pH 5.0)
containing 0.5 mg/ml of O-phenylenediamine (Sigma,
USA). Color was developed at 37°C and measured at 450
nm after the reaction was stopped with sulfuric acid at 2.5
mol/L.
Bronchoalveolar lavage
The trachea were exposed, cannulated and gently
instilled with 500 μl of cold PBS twice. The volume, total
cell number and composition of BAL samples were
recorded. Samples were centrifuged (× 500 g for 5 min-
utes at 4°C), resuspended and cytospined onto slides. Dif-
ferent cells from each sample were counted for 200 cells
in duplicate on coded slides. BAL fluid was stored at -
70°C and levels of the cytokines interleukin (IL)-4, IL-5
and interferon (INF)-γ were determined using specific
ELISA according to the use's manual (ELISA kits, eBiosci-
ence).
Histological evaluation
Twenty-four hours after the last allergen challenge, lungs
were harvested, fixed in 10% neutral-buffered formalin
and embedded in paraffin. Sections (5 μm) of specimens
were put onto 3-amino propyltriethoxy silane 3-Amino-
propyltriethoxysilane-coated slides. The tissues were
assessed for morphology and cellular infiltration using
haematoxylin and eosin (H&E) staining. The degree of
cellular infiltration was scored as described previously
[6]. Inflammatory changes were graded by histopatholog-
ical assessment using a semiquantitative scale of 0-5 for
perivascular eosinophilia, bronchiolar eosinophilia, epi-
thelial damage and oedema.
Generation of DCs from spleen and culture
Spleen DCs were enriched as described previously [7].
Briefly, after the spleen was disrupted, the cells were cen-
trifuged at 1300 rpm for 5 min, resuspended in RPMI
1640 medium supplemented with 10% heat-activated
fetal calf serum, 2 mmol/l L-glutamine, 1 mmol/l pyru-
vate, 50 μmol/l mercaptoethanol, 100 U/ml penicillin,
and 100 μg/ml streptomycin, and then incubated in plas-
tic cell cultures plates for 2 h at 37°C in a 5% CO2 atmo-
sphere. Culture plates were then washed thrice with
RPMI 1640 medium and nonadherent cells were dis-
carded. The residual adherent cells were maintained in
the culture medium and incubated overnight at 37°C in a
5% CO2 atmosphere. After incubation, DCs with the
adherence capacity in the first hours of culture become
nonadherent and float in the medium. The DCs were col-
lected and immediately used in the assays.
Detection of CD11c+CD80+and CD11c+CD86+surface markers 
on spleen DCs
DCs were harvested from the spleen, incubated with
FITC-labeled CD11c (eBioscience Inc.), PE-labeled anti-
CD80 (B7-1) mAb (eBioscience Inc.), and PE-labeled anti-
CD86 (B7-2) mAb (Southernbiotech) on ice for 30 min,
and washed with PBS thrice. Ten thousand cells were col-
lected from each sample and the data were analyzed with
flow cytometer and CELLQUEST software (Coulter, Bec-
ton Dickinson, USA). For the DC marker staining, DCs
were incubated with FITC-labeled rat anti-mouse IgG as
isotype control on ice for 30 min and washed. The
expression of the costimulatory molecules, i.e.
CD11c+CD80+and CD11c+CD86+, surface markers on spleen
DCs detected by FACS.
Detection of peripheral CD4+ and CD8+ T cells
Blood from mice was transferred into 6 × 50 ml Falcon
tubes using a 50 ml stripette and centrifuged at 1800 rpm
for 5 min. The supernatant was aspirated and pooled into
two of the tubes with PBS for a total volume of 75 ml. The
15 ml of Ficoll Paque was placed into three 50 ml tubes/
group.
25 ml of the diluted filter material was transferred onto
the Ficoll Paque so that they form two separate layers.
After the centrifugation at 1800 rpm for 20 min, the leu-
kocytes can now be collected at the interphase between
the Ficoll Paque and the plasma. The CD4+ and CD8+ T
cells were isolated from the peripheral blood were
detected by flow cytometry. After autologous CD4+ and
CD8+ T cells were stimulated with the targeted DCs, the
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Flow-cytometry assay was carried to detect the numbers
of peripheral CD4+ and CD8+ T cells in mice 24 h after the
last OVA challenge, using FITC-labeled CD4+ and CD8+
mAb, hemolytic agent( BD PharMingen) and IgG2a (Sero
Tec).
Detection of Foxp3+Tregs in spleen CD4+ T cells
We harvested CD4+ T cells of spleen from the various
groups using antibody-coated paramagnetic MultiSort
MicroBeads (MACS, Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturers protocol. After
detaching, CD4+ T cells were stained with CD25 Micro-
Beads (Miltenyi Biotec) and CD4+CD25+T cells were posi-
tively and negatively selected. Separation was controlled
by FCM and Spleen CD4+ T cells were labeled with
Mouse Regulatory T cell Staining Kit to detect the
expression of Foxp3+ in spleen CD4+ T cells (eBioscience
Inc.).
Statistical analysis
Data were expressed with means ± SD. Difference
between groups was analyzed using software SPSS for
windows (version 8.0) by unpaired two-tailed parametric
Student's t-test or ANOVA test. P-values less than 0.05
were considered statistically significant.
Results
Histological analysis demonstrated that significant airway
inflammation was observed in OVA-sensitized and chal-
lenged animals vaccinated with PBS or pcDNA3.1 plas-
mid, but less with OVA- pcDNA3.1 or OVA-Fc-pcDNA3.1
vaccination. The severity of leukocyte infiltration around
the central bronchi, alveoli and blood vessels was scored
and shown in Fig. 2. Leukocyte infiltration of the lungs
was reduced by vaccination with OVA plasmid compared
to vector alone. The thickness of small airway walls and
the number of infiltrated eosinophils around the airway
increased, eosinophils appeared within the lumen of the
airway, and goblet cell hyperplasia and hypertrophy
occurred in OVA-sensitized and challenged animals vac-
cinated with PBS (Fig. 2B) or pcDNA3.1 (C), as compared
with those sensitized and challenged with PBS (A). OVA
challenge led to a dense inflammatory infiltrate of lym-
phocytes, mononuclear and eosinophils as well as to epi-
thelial shedding, which was partially prevented by
immunization with pcDNA3.1 or OVA- pcDNA3.1 (Fig.
2D) and obviously by OVA-Fc-pcDNA3.1 (Fig. 2E).
As shown in Fig. 3A, serum levels of OVA-specific IgE
were significantly higher in OVA-sensitized and chal-
lenged mice vaccinated with PBS, as compared with these
sensitized, challenged and vaccinated with PBS (p < 0.01,
Fig. 3A). OVA-sensitized and challenged animals vacci-
nated with OVA-Fc-pcDNA3.1 had significantly lower lev-
els of OVA-specific IgE, as compared with those
vaccinated with PBS or pcDNA3.1 (p < 0.05). Animal vac-
cinated with pcDNA 3.1 plasmid had similar levels of
Figure 2 Histological findings of peripheral airway tissues (H&E, 
×100 origin) in PBS-vaccinated mice sensitized and challenged 
with PBS (A), PBS-vaccinated mice sensitized and challenged 
with ovalbumon (OVA) (B), pcDNA3.1-vaccinated mice sensitized 
and challenged with OVA (C), OVA- pcDNA3.1-vaccinated mice 
sensitized and challenged with OVA (D), and OVA-Fc-pcDNA3.1-
vaccinated mice sensitized and challenged with OVA (E).
Figure 3 Serum levels of OVA-specific IgE (A) and the number of 
eosinophils in bronchoalveolar lavage (BAL) fluid (B) in PBS-vac-
cinated mice sensitized and challenged with PBS, PBS-vaccinated 
mice sensitized and challenged with ovalbumon (OVA), 
pcDNA3.1-vaccinated mice sensitized and challenged with OVA, 
OVA- pcDNA3.1-vaccinated mice sensitized and challenged with 
OVA, and OVA-Fc-pcDNA3.1-vaccinated mice sensitized and chal-
lenged with OVA. * and ** stand for the p values less than 0.05 and 
0.01, respectively, as compared with PBS-vaccinated mice sensitized 
and challenged with PBS. + and ++ stand for the p values less than 0.05 
and 0.01, respectively, as compared with OVA-Fc-pcDNA3.1-vaccinated 
mice sensitized and challenged with OVA.
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pcDNA3.1. The number of eosinophils in BAL fluid of
OVA mice vaccinated with PBS or pcDNA 3.1 was signifi-
cantly higher than those without OVA (p < 0.01, Fig. 3B).
Immunization with OVA-Fc-pcDNA3.1 significantly pre-
vented OVA-induced eosinophilia in BAL fluid, as com-
pared with that with PBS, pcDNA3.1 or OVA-pcDNA3.1 (p
< 0.01 or 0.05, respectively). Vaccination with OVA-
pcDNA3.1 partially prevented from OVA-increased num-
ber of eosinophils (p < 0.05, vs PBS or pcDNA3.1, respec-
tively). OVA induced a significant elevation of IL-4 BAL
fluid in all animals, as compared with animals without
OVA (p < 0.01 or 0.05, respectively, Fig. 4A), while OVA-
Fc-pcDNA3.1 showed partially preventive effects (p <
0.05, vs OVA animals vaccinated with PBS). The BAL lev-
els of IL-5 in OVA animals vaccinated with PBS,
pcDNA3.1 or Fc-pcDNA3.1 were significantly higher than
those without OVA, which was significantly prevented by
OVA-Fc-pcDNA3.1, as compared with pcDNA3.1 or Fc-pc
(p < 0.01, respectively, Fig. 4B). Immunization with OVA-
Fc-pcDNA3.1 also significantly prevented OVA-reduced
level of INF-γ in BAL fluid, as immunization with PBS or
pcDNA3.1 (p < 0.05, Fig. 4C).
We isolated spleen-derived DCs from all animals, iden-
tified the characteristics of these DCs expressed CD11c
molecule, detected OVA-increased expression of CD80+
and CD86+ on DCs obtained from the spleen, and then
evaluated the preventive effects of OVA-Fc-pcDNA3.1 on
the expression of CD80+ and CD86+ on DCs obtained from
the spleen of OVA-sensitized and challenged mice. OVA
induced a significant expression of CD11c+CD80+ (Fig. 5A)
and CD11c+CD86+ (Fig. 5B) on spleen DCs harvested from
mice vaccinated with PBS or pcDNA3.1, as compared with
those without OVA (p < 0.05), which was significantly
prevented by the vaccination with OVA-Fc-pcDNA3.1.
Our pilot study showed that targeted DCs stimulated
the proliferation of peripheral CD4+ T and CD8+ T cells in
a concentration-dependent pattern. The proliferation of
both peripheral CD8+ (Fig. 6A) and CD4+ T cells (Fig. 6B)
in OVA mice vaccinated with PBS or pcDNA3.1 was sig-
nificantly lower than those without OVA (p < 0.01 or
0.05, respectively). Vaccination with OVA-Fc-pcDNA3.1
significantly prevented OVA-suppressed cell proliferation
(p < 0.05). The expression of Foxp3+ on spleen CD4+ T
cells were significantly suppressed by OVA mice vacci-
nated with PBS, pcDNA3.1 and Fc-pcDNA3.1 (p < 0.01,
respectively, Fig. 6C), but not with OVA-Fc-pcDNA3.1.
Figure 4 Levels of interleukin-4 (A), interleukin-5 (B) and interfer-
on gamma (C) in bronchoalveolar lavage (BAL) fluid (B) in PBS-
vaccinated mice sensitized and challenged with PBS, PBS-vacci-
nated mice sensitized and challenged with ovalbumon (OVA), 
pcDNA3.1-vaccinated mice sensitized and challenged with OVA, 
OVA- pcDNA3.1-vaccinated mice sensitized and challenged with 
OVA, and OVA-Fc-pcDNA3.1-vaccinated mice sensitized and chal-
lenged with OVA. * and ** stand for the p values less than 0.05 and 
0.01, respectively, as compared with PBS-vaccinated mice sensitized 
and challenged with PBS. + and ++ stand for the p values less than 0.05 
and 0.01, respectively, as compared with OVA-Fc-pcDNA3.1-vaccinated 
mice sensitized and challenged with OVA.
Figure 5 Expression of CD11c+CD80+ (A) and CD11c+CD86+ (B) on 
spleen dendritic cells harvested from PBS-vaccinated mice sensi-
tized and challenged with PBS, PBS-vaccinated mice sensitized 
and challenged with ovalbumon (OVA), pcDNA3.1-vaccinated 
mice sensitized and challenged with OVA, OVA- pcDNA3.1-vacci-
nated mice sensitized and challenged with OVA, and OVA-Fc-
pcDNA3.1-vaccinated mice sensitized and challenged with OVA. * 
stands for the p values less than 0.05, as compared with PBS-vaccinat-
ed mice sensitized and challenged with PBS. + stands for the p values 
less than 0.05, as compared with OVA-Fc-pcDNA3.1-vaccinated mice 
sensitized and challenged with OVA.
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The results from the present study demonstrated that
allergen-DNA-targeted DCs were highly effective in pre-
venting allergen-induced airway inflammation in a
murine allergic model. OVA-sensitization and challenge
could induced the development of airway inflammation
and Th2 responses and suppressed the proliferation of
peripheral CD4+and CD8+ T cells and the expression of
Foxp3+ Treg in spleen, which could be prevented by the
vaccination with OVA-Fc-pcDNA3.1. The potential mech-
anisms of OVA-Fc-pcDNA3.1 effects may be that Fc
enhancing DC absorption is more powerful in stimulat-
ing the production of TH1 cytokine synthesis in naïve and
memory T cells.
As an alternative to the administration of allergens or
allergen derivatives, vaccination with allergen-encoding
DNA has been proposed as a strategy for SIT [8-10]. Den-
dritic cells are uniquely situated in the immune cascade
to initiate and modulate airway immune responses [11-
13]. In addition, immature DCs express a number of spe-
cific chemokine receptors, FcR, and Toll-like receptors,
through which the DCs are developing [14-16]. DCs can
be activated or inhibited through FcR by antibodies or
immune complex formed by antibodies depending on the
variations of FcR engaged. Activating and inhibitory IgG
Fc receptors on DCs mediate opposing functions [17,18]
DNA vaccination may directly target DCs involved in
allergen-specific TH1-cell responses, showing preventive
effects when delivered in mice [19-23]. The vaccination
with OVA-pcDNA3.1 or OVA-Fc-pcDNA3.1 showed pre-
ventive effects on OVA-induced hyper-production of IL-
4 and IL-5 and hypo-production of INF-γ, and eosinophil
infiltration, while the effects of OVA-Fc-pcDNA3.1 were
more significant. Our study suggested that DNA vaccine
encoding both mouse Fc and OVA was more effective
than DNA vaccine encoding only OVA in suppressing
airway inflammation.
We found that local exposure to OVA resulted in an
increased number of spleen DCs expressing CD11c+CD80
and CD11c+CD86 molecules, similar to the previous find-
ings [24], suggesting that CD80 and CD86 molecules act as
the regulators of immune responses. The CD80 and CD80,
as the most important costimulatory molecules, could
play the important role in the allergic immune responses,
indicating that the effective cross-presentation and DC
maturation should be considered in the development of
efficacious targeting strategies. Our results also showed
that OVA-induced Tregs decrease could also be pre-
vented by the allergen-DNA-targeted-DCs, suggesting
that the allergen-DNA-targeted-DC may be useful in SIT
and the restoration of Tregs played a key role in success-
ful SIT.
Costimulatory molecules as potential targets contrib-
ute to the therapeutic intervention in allergic airway dis-
ease, which could be treated with DCs activated by cross-
linking B7-DC [25-28]. Spleen DCs function could be
modulated following SIT. Immune complexes of IgG and
antigen can be internalized via FcRs on DC, resulting in
DC maturation and priming of antigen-specific CD8+T
cells in vivo[29,30]. However, DCs express both activating
and inhibitory FcRs, and the balance between activating
and inhibitory signaling will determine whether uptake of
immune complexes results in naive T cell activation and
protective immunity [31]. The OVA-Fc-pcDNA3.1 influ-
enced those surface marker expressions on targeted DCs,
probably down-regulating general capability of DCs to
present antigen [32-34]. Spleen DCs have a partially
mature phenotype and express a range of co-stimulatory
molecules that are intermediate between immature and
mature DCs, resulting in tolerogenic interaction with T
cells in SIT. We found that the combination of DNA vac-
cination with Fc and OVA had better effects onOVA-
induced alterations in the spleen. It is evidenced by the
previous findings that DNA vaccination suppressed both
Th1 and Th2 responses (IFN-γ and IL-4 production from
spleen cells) [34-36]. It would be more interesting to
explore the potential mechanisms of CD11c+CD80 and
CD11c+CD86 induction and regulation between DCs and
Tregs in the further studies.
Figure 6 Proliferation of peripheral CD4+ (A) and CD8+ T cells (B) 
and the expression of Foxp3+ on spleen CD4+ T cells (C) harvested 
from PBS-vaccinated mice sensitized and challenged with PBS, 
PBS-vaccinated mice sensitized and challenged with ovalbumon 
(OVA), pcDNA3.1-vaccinated mice sensitized and challenged with 
OVA, OVA- pcDNA3.1-vaccinated mice sensitized and challenged 
with OVA, and OVA-Fc-pcDNA3.1-vaccinated mice sensitized and 
challenged with OVA. * and ** stand for the p values less than 0.05 
and 0.01, respectively, as compared with PBS-vaccinated mice sensi-
tized and challenged with PBS. + and ++ stand for the p values less 
than 0.05 and 0.01, respectively, as compared with OVA-Fc-pcDNA3.1-
vaccinated mice sensitized and challenged with OVA.
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ing of antigens to DC surface receptors elicits effective
immune responses [37-42], although it is still question-
able that the certain surface receptors can make more
suitable targets than others. Immunization with OVA-Fc-
pcDNA3.1 could prevent OVA-induced over-formation of
allergen-specific IgE, local hyper-production of IL-4 and
IL-5 and hypo-production of INF-γ, over-expression of
costimulatory molecules CD11c+CD80+and CD11c+CD86+in
spleen, and finally airway inflammation. Thus, DNA vac-
cine encoding OVA directly to DCs may a new alternative
of therapies for patients with allergic asthma. These find-
ings suggest that spleen DCs and Foxp3+Tregs prevents
the generation and activation of Th2 effector cells as a
novel pathway of regulation of type 2 immunity in
asthma.
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